Menu
At Lumos Care, we offer medically supervised weight loss through GLP-1 (Semaglutide) injection therapy, the same class of medication as Ozempic® and Wegovy®. Our program includes a once-weekly, self-administered injection, combined with a healthy diet and regular exercise, to help you achieve sustainable weight loss.
Clinical studies have shown that participants using GLP-1 therapy experienced an average weight reduction of 5.9% within 3 months and 10.9% after 6 months.
GLP-1 medications target the hunger center in the brain, helping you feel fuller faster and for longer periods, reducing appetite, and promoting a sense of satisfaction after meals.
Lumos now offers Tirzepatide injection therapy, an advanced option for those seeking enhanced weight loss results. Tirzepatide is a dual-action medication that targets both GLP-1 and GIP receptors, setting it apart from traditional GLP-1 therapies like Semaglutide. This dual mechanism has been shown to significantly boost weight loss and appetite control.
In clinical trials, participants using Tirzepatide achieved up to 15% body weight reduction within just 6 months—making it one of the most powerful weight loss treatments available today.
Tirzepatide helps regulate appetite by slowing digestion and reducing hunger, helping you feel satisfied with smaller portions. With a simple, once-weekly injection, it can accelerate your weight loss journey when combined with healthy lifestyle changes.